Thus, NF-κB drives tumor progression by coupling cancer-intrinsic glycolytic/OXPHOS reprogramming with immunosuppressive immunometabolism in the TME to sustain both tumor survival and immune evasion. The gene discussed is NFKB1; the disease is neoplasm.